SARM Sample Clauses
The SARM (Shared Appreciation Mortgage) clause defines the terms under which a lender and borrower agree to share in the appreciation of a property's value upon its sale or refinancing. Typically, this clause stipulates that in addition to repaying the principal and interest, the borrower will pay the lender a percentage of any increase in the property's value realized during the loan period. For example, if a home increases in value by a certain amount, the lender receives a pre-agreed share of that gain. The core function of this clause is to align the interests of both parties and allow the lender to participate in the upside of property appreciation, while potentially offering the borrower lower initial interest rates or more favorable loan terms.
SARM. Viking shall pay Ligand the following one-time, non-refundable milestone payments with respect to Licensed Products containing a SARM Compound as follows: The end of the […***…] during which cumulative Net Sales for all Licensed Products containing a SARM Compound reach or surpass […***…] […***…] The end of the […***…] during which cumulative Net Sales for all Licensed Products containing a SARM Compound reach or surpass […***…] […***…] The end of the […***…] during which cumulative Net Sales for all Licensed Products containing a SARM Compound reach or surpass […***…] […***…]
SARM. Viking shall, during the applicable Royalty Term, pay to Ligand a royalty on aggregate annual worldwide Net Sales by Viking and its Affiliates and Sublicensees of all Licensed Products with one or more Valid Claims Covering any SARM Compound contained in such Licensed Products, at the percentage rates set forth below: For Net Sales of such a Licensed Product from […***…] up to and including […***…] […***…]% For that portion of Net Sales of a Licensed Product that is greater than […***…] and less than or equal to […***…] […***…]% For that portion of Net Sales of a Licensed Product that is greater than […***…] […***…]% By way of illustration, assume in a Calendar Year that aggregate worldwide annual Net Sales of all such Licensed Products total $950,000,000. The total royalties due and payable by Viking to Ligand for such Net Sales would be […***…], calculated as follows: […***…]
SARM. Viking shall, during the applicable Royalty Term, pay to Ligand a royalty on aggregate annual worldwide Net Sales by Viking and its Affiliates and Sublicensees of all Licensed Products with one or more Valid Claims Covering any SARM Compound contained in such Licensed Products, at the percentage rates set forth below: For Net Sales of such a Licensed Product from [***] up to and including [***] [***]% For that portion of Net Sales of a Licensed Product that is greater than [***] and less than or equal to [***] [***]% For that portion of Net Sales of a Licensed Product that is greater than [***] [***]% By way of illustration, assume in a Calendar Year that aggregate worldwide annual Net Sales of all such Licensed Products total $950,000,000. The total royalties due and payable by Viking to Ligand for such Net Sales would be [***], calculated as follows: [***]
SARM. Viking shall pay Ligand the following one-time, non-refundable milestone payments with respect to Licensed Products containing a SARM Compound as follows: ***Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. The end of the [***] during which cumulative Net Sales for all Licensed Products containing a SARM Compound reach or surpass [***] [***] The end of the [***] during which cumulative Net Sales for all Licensed Products containing a SARM Compound reach or surpass [***] [***] The end of the [***] during which cumulative Net Sales for all Licensed Products containing a SARM Compound reach or surpass [***] [***]